ClinicalTrials.gg
RecruitingNCT06352632Updated Nov 10, 2026

ACT-GLOBAL Adaptive Platform Trial for Stroke

A Phase 3 interventional study of Standard-dose intravenous tenecteplase and Low-dose intravenous tenecteplase in Stroke, sponsored by The George Institute. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by The George Institute · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.
Updated Nov 10, 2026Interventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies testing tenecteplase in Stroke — 10 open to participants now, 10 under way, 9 of them phase 3. Tenecteplase · Stroke.

Planned enrollment
Largest of 28
20,000 · median 337
Started
2024
with 1 other
Phase 3
15 of 28
7 open now
Registered
22nd of 28
by date

Among the 28 studies testing tenecteplase in Stroke, this one has the largest planned enrollment, is one of 2 that started in 2024, is one of 15 in phase 3, and was the 22nd registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

10 of the 28 studies testing tenecteplase in Stroke are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About tenecteplase

Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tenecteplase in Stroke, or all of them as a file.
02

Study summary

Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.

Read the detailed description

Stroke is the second leading cause of death, worldwide. It is also the second largest cause of disability-adjusted-life-years (DALYs) lost after ischaemic heart disease in developing countries, and third largest contributor to DALYs in developed countries (after ischaemic heart disease, low back and neck pain). In 2019, the absolute numbers of new strokes (12.2 million), stroke-related deaths (6.6 million), and people living with stroke (101.5 million) had increased globally from 1990 (70%, 43%, and 85% increases, respectively).

Steady progress has been made in establishing specific management strategies for patients affected by, or at high-risk of, stroke. Unfortunately, only a few acute treatments have been proven to be beneficial: thrombolysis, endovascular thrombectomy, hemicraniectomy, stroke unit care, and aspirin. There is a continued need for interventions that improve outcomes which can be implemented with wide applicability for stroke.

ACT-GLOBAL is an investigator-initiated, multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to find the treatment/s associated with the highest chance of improving outcome after stroke. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.

Frequent adaptive analyses are conducted to assess whether a given intervention is superior, inferior, or equivalent either within a domain or for specific populations within the domain. Where it is anticipated that interactions between interventions in different domains may be likely, the statistical models will allow evaluation of such interactions. Each intervention within a domain with prospectively defined and mutually exclusive strata (sub-groups) of participants will be evaluated within the strata, while information from one stratum may be used (via 'borrowing') to contribute to the analysis of the effect of that intervention in other strata. Specific interventions or subgroups within overall populations may be dropped or cease to enrol, based on pre-specified rules.

The adaptive design allows new interventions or domains or both to be introduced. A Response Adaptive Randomisation algorithm may be used to preferentially randomize participants to interventions that appear to be performing better in domains where applicable.

Unlike traditional trial designs which explicitly prohibit co-enrollment of patients into different trials or multiple therapies, or use a factorial design, the adaptive platform design allows investigators to replicate the real-world environment to estimate possible synergy, competitive interference, or safety profiles of complex treatment protocols.

The ACT-GLOBAL platform is organized into four states defined by stroke type, treatment phase, or therapeutic purpose: Acute Ischemic Stroke (AIS), Intracerebral Hemorrhage (ICH), Secondary Prevention, and Rehabilitation. AIS and ICH are acute stroke-type states, whereas Secondary Prevention and Rehabilitation are therapeutic-purpose states that can span stroke types. Eligibility is assessed hierarchically at platform, state, and domain levels. State subprotocols provide the clinical framework, and domain-specific appendices define additional eligibility criteria, intervention comparisons, procedures, outcomes, follow-up, and analysis requirements.

The AIS State includes patients with a clinical diagnosis of acute ischemic stroke; the ICH State requires confirmation of intracerebral hemorrhage by brain imaging. Core functional outcome assessments use the modified Rankin scale at 90 days in AIS and at 6 months in ICH, with domain-specific requirements specified in the relevant appendices.

The Secondary Prevention State addresses prevention of recurrent stroke and other vascular events after stroke or transient ischemic attack. The index event must have been clinically assessed and the participant sufficiently stable for the relevant intervention. Domains may evaluate antithrombotic, blood pressure, lipid or metabolic, cardiac-monitoring, vascular or procedural, adherence, lifestyle, or service-delivery strategies. Each domain prospectively specifies its own primary outcome and follow-up schedule; the state does not mandate a single universal primary outcome.

The Rehabilitation State includes medically stable adults with stroke who have a rehabilitation need or a personally meaningful goal relevant to an active domain. Domains may evaluate therapy timing or dose, mobility, upper-limb function, activities of daily living, cognition, communication, swallowing, mood or fatigue, technology or telerehabilitation, care transitions, or service delivery. Each domain prespecifies an appropriate primary outcome and assessment time. For broad pragmatic or service-delivery domains, the preferred default is the Barthel Index or a validated activities-of-daily-living measure at 6 months; targeted domains use a construct-valid target-specific outcome. Domain availability and intervention eligibility are determined by the relevant protocol and participating site. Additional states and domains may be introduced through platform governance and applicable approvals.

CoPRIME is a planned phase 2a safety and feasibility domain within the Secondary Prevention State. Under the updated CoPRIME protocol (DAPT062026, version 1.0, 18 September 2026), 300 eligible adults with non-cardioembolic acute ischemic stroke treated with intravenous thrombolysis and/or endovascular thrombectomy will be randomized 1:1:1 to aspirin alone, aspirin plus clopidogrel, or aspirin plus ticagrelor for 21 days, with follow-up to 90 days. As of 5 November 2026, the updated protocol has been submitted to Health Canada and has not yet enrolled participants. NCT07844603 remains the CoPRIME registration; enrolment under the earlier protocol is distinct from enrolment under the updated protocol.

03

Conditions studied

  • Stroke

Keywords

  • Adaptive Platform Trial
  • Blood Pressure
  • Tenecteplase
  • Ischaemic stroke
  • Intracerebral Haemorrhage
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Platform Inclusion Criteria:

  1. Age ≥18 years
  2. Clinical diagnosis of stroke

Platform Exclusion Criteria:

There are no platform level exclusion criteria

Each state and domain will specify additional inclusion and exclusion criteria in the respective Domain-Specific Registration. Patients who fulfill the overall platform criteria will be assessed for enrollment into each active domain.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
20,000 participants (estimated)

Study arms

  • Experimental
    IV thrombolysis domain

    This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design to optimize the use of intravenous Tenecteplase in participants with Acute Ischemic Stroke.

    Drug: Standard-dose intravenous tenecteplase · Drug: Low-dose intravenous tenecteplase · Other: No intravenous tenecteplase

  • Experimental
    Blood Pressure domain

    Third Enhanced Control of Hypertension and Thrombectomy Stroke Study (ENCHANTED3/MT) as a domain of ACT-GLOBAL to compare three BP lowering management strategies, that of conservative, moderate and intensive BP lowering in patients with Acute Ischaemic Stroke admitted to participating hospitals who has an elevated SBP after reperfusion therapy via Endovascular Thrombectomy, and reliably determine, which approach leads to improved functional outcome. Locally available and approved i.v. BP lowering agents can be used in this domain.

    Other: Conservative Blood Pressure Control · Other: Moderate Blood Pressure Control · Other: Intensive Blood Pressure Control

  • Experimental
    ACT-42 domain

    This domain has a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive design and aim to determine the efficacy and safety of NoNO-42 in participants with Acute Ischaemic Stroke selected for thrombolysis with or without Endovascular Thrombectomy.

    Other: Placebo · Drug: NoNO-42

  • Experimental
    INTERACT5 Domain

    This is a domain within the Intracerebral Haemorrhage State of the ACT-GLOBAL adaptive platform trial for stroke. The objective of this domain is to determine the efficacy of intravenous deferoxamine and low-dose oral colchicine, both individually and in combination, compared to standard of care alone, on improving functional outcome in patients with acute spontaneous supratentorial ICH.

    Other: No deferoxamine mesylate and no colchicine · Drug: Deferoxamine mesylate only · Drug: Colchicine only · Drug: Both deferoxamine mesylate and colchicine

  • Experimental
    IA Thrombolysis Domain

    This domain will be conducted as part of ACT-GLOBAL platform trial and will have the nested domain name of REACT. This domain aims to efficiently, reliably, and simultaneously, determine the effectiveness of targeted intraarterial (IA) thrombolysis using either tenecteplase or alteplase vs. no IA thrombolysis in all patients who undergo EVT. It has a prospective, randomised, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design of up to 1,500 subjects with AIS who undergo EVT. Randomisation will be stratified by country/ region, and the IA thrombolytic agent (tenecteplase or alteplase). Minimal sufficient balance algorithm will operate within each stratum to preserve balance on key covariates while maintaining allocation randomness. The duration of follow-up is 90 days. Primary outcome will be mRS, conducted through centralized telephone interviews or online media performed by central trial personnel blinded treatment assignment and received.

    Drug: IA thrombolysis · Other: no IA thrombolysis

  • Experimental
    IMP-ACT domain

    This is a randomized, open-label, blinded-endpoint, phase 3 domain within the Acute Ischemic Stroke State. Up to 800 adults with stroke due to medium-vessel occlusion are randomized to usual care, mechanical endovascular thrombectomy (EVT) without intra-arterial (IA) thrombolysis, or mechanical EVT followed by adjunctive IA thrombolysis with tenecteplase or alteplase. Usual medical and stroke-unit care is provided in all groups; intravenous thrombolysis may be given when eligible. Participants are followed for 90 days. Treatment details are specified in the IMP-ACT domain registration (NCT07906275).

    Other: IMP-ACT usual care · Procedure: IMP-ACT mechanical endovascular thrombectomy · Drug: Intra-arterial tenecteplase or alteplase in IMP-ACT

  • Experimental
    CoPRIME domain

    CoPRIME is a planned phase 2a, multicentre, randomized, open-label, blinded-endpoint safety and feasibility domain within the Secondary Prevention State of ACT-GLOBAL. It will enrol 300 eligible adults with non-cardioembolic acute ischemic stroke treated with intravenous thrombolysis and/or endovascular thrombectomy. Eligible participants are randomized 1:1:1 within 30 hours after the end of acute reperfusion therapy, after a post-reperfusion non-contrast CT and with NIHSS \<=10 at randomization, to aspirin alone, aspirin plus clopidogrel, or aspirin plus ticagrelor for 21 days. Study treatment starts within 60 minutes of randomization, and participants are followed for 90 days. As of 5 November 2026, the updated protocol has been submitted to Health Canada; the domain remains in the planning phase, with no enrolment under the updated protocol. Domain registration: NCT07844603.

    Drug: CoPRIME aspirin alone · Drug: CoPRIME aspirin plus clopidogrel · Drug: CoPRIME aspirin plus ticagrelor

Interventions

  • DrugTenecteplaseStudies of TenecteplaseTenecteplase pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Standard-dose intravenous tenecteplase (0.25 mg/kg body weight); one-time IV bolus injection soon after randomisation

  • DrugTenecteplaseStudies of TenecteplaseTenecteplase pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Low-dose intravenous tenecteplase (0.18 mg/kg body weight); one-time IV bolus injection soon after randomisation

  • OtherNo intravenous tenecteplase

    No intravenous tenecteplase only in subjects on direct oral anticoagulant (DOACs) or those planned for emergency endovascular thrombectomy (EVT)

  • OtherConservative Blood Pressure Control

    No or minimal Systolic Blood Pressure (SBP) control; SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP (≥180mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)

  • OtherModerate Blood Pressure Control

    SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP (150-160mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)

  • OtherIntensive Blood Pressure Control

    SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher after endovascular thrombectomy (EVT); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)

  • OtherPlacebo

    100 mL of 0.9% normal saline, administered as a single IV infusion with a 20-minute dosing duration.

  • NoNO-42 at weight-based dosing - 2.6 mg/Kg, administered as a single IV infusion with a 20-minute dosing duration

  • OtherNo deferoxamine mesylate and no colchicine

    No deferoxamine mesylate and no colchicine

  • DrugDeferoxamine mesylate only

    Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days

  • DrugColchicine only

    0.5mg of oral colchicine daily for 30 days

  • DrugBoth deferoxamine mesylate and colchicine

    Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days; plus 0.5mg of oral colchicine daily for 30 consecutive days

  • DrugIA thrombolysis

    Participants randomised to the IA thrombolysis group will receive IA thrombolysis (tenecteplase or alteplase) at the time of completion of the mechanical thrombectomy part of the EVT procedure. Tenecteplase will be given at a dose of 0.0625mg/kg (maximum dose of 6.25mg) and alteplase at a dose of 0.225 mg/kg (maximum dose 22.5mg) intraarterially by the treating neuro-interventional staff. The selection of thrombolytic agent will be determined according to local availability. The study drug dose will be increased to 0.125 mg/ kg (maximum dose 12.5mg) for tenecteplase or 0.45 mg/kg (maximum dose 40mg) for alteplase if above dose meet prespecified posterior probabilities at the first or second interims per adaptive design report.

  • Otherno IA thrombolysis

    Participants randomised to the No IA thrombolysis group will not receive IA thrombolysis.

  • OtherIMP-ACT usual care

    Usual medical and stroke-unit care, including intravenous thrombolysis when eligible. This is the usual-care strategy in IMP-ACT (NCT07906275), without assigned mechanical endovascular thrombectomy or adjunctive intra-arterial thrombolysis.

  • ProcedureIMP-ACT mechanical endovascular thrombectomy

    Mechanical endovascular thrombectomy (EVT) using tools and techniques selected by the treating neurointerventionalist. This procedure is used in both EVT strategies in IMP-ACT (NCT07906275); the EVT-alone strategy does not include intra-arterial thrombolysis.

  • DrugIntra-arterial tenecteplase or alteplase in IMP-ACT

    Adjunctive intra-arterial tenecteplase or alteplase delivered by microcatheter into the affected arterial territory following mechanical endovascular thrombectomy. The agent is selected according to local availability. This intervention is used only in the EVT-plus-intra-arterial-thrombolysis strategy. Regimen details are specified in the IMP-ACT domain registration (NCT07906275).

  • DrugCoPRIME aspirin alone

    Aspirin 160 mg on day 1, followed by 81 mg once daily on days 2-21. Study treatment starts within 60 minutes of randomization. This is the aspirin-alone strategy in CoPRIME.

  • DrugCoPRIME aspirin plus clopidogrel

    Aspirin 160 mg plus clopidogrel 300 mg on day 1, followed by aspirin 81 mg once daily plus clopidogrel 75 mg once daily on days 2-21. Study treatment starts within 60 minutes of randomization. This is the aspirin-plus-clopidogrel strategy in CoPRIME.

  • DrugCoPRIME aspirin plus ticagrelor

    Aspirin 160 mg plus ticagrelor 180 mg on day 1, followed by aspirin 81 mg once daily plus ticagrelor 90 mg twice daily on days 2-21. Study treatment starts within 60 minutes of randomization. This is the aspirin-plus-ticagrelor strategy in CoPRIME.

06

What researchers measure

Primary outcomes

  1. modified Rankin scale (mRS) scores

    The mRS is a 7-outcome ordered categorical scale that assesses functional neurological status after stroke. It is not intended for use as a measure of historical functional status. It is well accepted as a standard outcome around the world in the stroke community, by patients and by regulatory authorities. The seven values and the clinical summary of the individual scores are summarized in the following: 0 = No symptoms 1. = No significant disability; able to carry out all usual activities 2. = Slight disability; can look after own affairs, but unable to carry out all previous activities 3. = Moderate disability; require some help 4. = Moderately severe disability; unable to attend to own bodily needs without assistance 5. = Severe disability; bedridden and requiring constant nursing care and attention 6. = Dead

    Time frame: Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; Domain specific time frame may differ (details will be included in domain-specific registration)

Secondary outcomes

  1. Excellent functional neurological outcome

    Excellent functional neurological outcome means modified Rankin scale (mRS) scores 0-1. The minimum mRS is 0 (no symptoms) while the maximum mRS is 6 (death). The higher the mRS score is the worse outcome is.

    Time frame: Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; Domain specific time frame may differ (details will be included in domain-specific registration)

  2. Independent functional neurological outcome

    Independent functional neurological outcome means modified Rankin scale (mRS) scores 0-2. The minimum mRS is 0 (no symptoms) while the maximum mRS is 6 (death). The higher the mRS score is the worse outcome is.

    Time frame: Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; Domain specific time frame may differ (details will be included in domain-specific registration)

  3. Health Related Quality of Life

    Health Related Quality of Life based on EuroQol 5 Dimension 5 Level (EQ-5D-5L).The EQ-5D-5L is a generic instrument for describing and valuing health. It is based on a descriptive system that defines health in terms of five dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has five response categories corresponding to: no problems, slight, moderate, severe and extreme problems.

    Time frame: Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; Domain specific time frame may differ (details will be included in domain-specific registration)

Other outcomes

  1. Mortality

    Mortality status equals to death which will be collected at all visits during the trial period

    Time frame: Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; State and Domain specific time frame may differ (details will be included in domain-specific registration)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — After a domain is completed, the archived de-identified limited dataset of randomized participants will be transmitted to and stored in the ACT-GLOBAL Data Repository, for use by researchers. Data can be shared after publication of the main results unless specified otherwise in domain-specific registration.

Supporting information: Study protocol

Time frame: Data can be shared after publication of the main results.

Access criteria: Data can be shared after publication of the main results, based on approval of a submitted protocol to the Publication Committee and relevant ethics review. Data can be shared to bona fide researchers with experience in medical research, and with no conflict of interest that may potentially influence their interpretation of any analyses, and employed by a recognised academic institute, health service organisation, commercial research organisation of from the pharmaceutical industry. The data sharing will be only for analyses within the constraints of the consent under which the data were originally gathered consent. Data sharing with industry will be according to relevant contracts with appropriate approvals from all stake holders.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2034, 120 months after the start.

Of 93 non-industry phase 3 interventional studies under Stroke, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 120 months is above that.

Counting every sponsor, half of 130 studies reached it within 44 months; a quarter within 27 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2024
First posted
Apr 8, 2024
StartActual
Sep 26, 2024
Primary completionEst.
Sep 2034
CompletionEst.
Sep 2034
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Added IMP-ACT usual care·Procedure: IMP-ACT mechanical endovascular thrombectomy·Drug: Intra-arterial tenecteplase or alteplase in IMP-ACT·Drug: CoPRIME aspirin alone·Drug: CoPRIME aspirin plus clopidogrel·and 1 more
All 6

IMP-ACT usual care · Procedure: IMP-ACT mechanical endovascular thrombectomy · Drug: Intra-arterial tenecteplase or alteplase in IMP-ACT · Drug: CoPRIME aspirin alone · Drug: CoPRIME aspirin plus clopidogrel · Drug: CoPRIME aspirin plus ticagrelor

. Arms added: IMP-ACT domain·CoPRIME domain
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Interventions Added IMP-ACT usual care·Procedure: IMP-ACT mechanical endovascular thrombectomy·Drug: Intra-arterial tenecteplase or alteplase in IMP-ACT·Drug: CoPRIME aspirin alone·Drug: CoPRIME aspirin plus clopidogrel·and 1 more
    All 6

    IMP-ACT usual care · Procedure: IMP-ACT mechanical endovascular thrombectomy · Drug: Intra-arterial tenecteplase or alteplase in IMP-ACT · Drug: CoPRIME aspirin alone · Drug: CoPRIME aspirin plus clopidogrel · Drug: CoPRIME aspirin plus ticagrelor

    . Arms added: IMP-ACT domain·CoPRIME domain
    + 3 other changes: description, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06352632
Lead sponsor
The George Institute
Collaborators
University of Calgary, Berry Consultants
Responsible party
Sponsor
First posted
Apr 8, 2024
Start date
Sep 26, 2024
Primary completion
Sep 2034 (estimated)
Completion
Sep 2034 (estimated)
Last update
Nov 10, 2026

Study contacts

Xiaoying Chen, PhD
Contact
xchen@georgeinstitute.org.au
+61280524549
Bijoy Menon, MD, PhD
Contact
docbijoymenon@gmail.com
+14033381198
Craig Anderson, MD, PhD
principal investigator · The George Institute
Bijoy Menon, MD
principal investigator · University of Calgary
Michael D Hill, MD
principal investigator · University of Calgary
Andrew Demchuk, MD
principal investigator · University of Calgary
Xiaoying Chen, PhD
principal investigator · The George Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tenecteplase · NONO-42

Start the discussion